Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.

Gorden P, Park JY.

Arch Physiol Biochem. 2006 Apr;112(2):114-8. Review.

PMID:
16931453
2.

The clinical uses of leptin.

Gorden P, Gavrilova O.

Curr Opin Pharmacol. 2003 Dec;3(6):655-9. Review.

PMID:
14644019
3.

Rethinking leptin and insulin action: therapeutic opportunities for diabetes.

Yildiz BO, Haznedaroglu IC.

Int J Biochem Cell Biol. 2006;38(5-6):820-30. Epub 2005 Oct 3. Review.

PMID:
16236542
4.

Leptin-replacement therapy for lipodystrophy.

Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A.

N Engl J Med. 2002 Feb 21;346(8):570-8.

5.

[Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].

Jazet IM, Jonker JT, Wijngaarden MA, Lamb H, Smelt AH.

Ned Tijdschr Geneeskd. 2013;157(4):A5482. Review. Dutch.

PMID:
23343738
6.

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI.

J Clin Invest. 2002 May;109(10):1345-50.

7.

Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.

Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P.

Diabetes. 2005 Jul;54(7):1994-2002.

8.

Hypothalamic melanocortin signaling and leptin resistance--perspective of therapeutic application for obesity-diabetes syndrome.

Masuzaki H, Tanaka T, Ebihara K, Hosoda K, Nakao K.

Peptides. 2009 Jul;30(7):1383-6. doi: 10.1016/j.peptides.2009.04.008. Epub 2009 Apr 23. Review.

PMID:
19394382
9.

The clinical utility of leptin therapy in metabolic dysfunction.

Park JY, Gavrilova O, Gorden P.

Minerva Endocrinol. 2006 Jun;31(2):125-31. Review.

PMID:
16682936
10.

Health risks of lipodystrophy and abdominal fat accumulation: therapeutic possibilities with leptin and human growth hormone.

Van Gaal LF, Mertens IL, Abrams PJ.

Growth Horm IGF Res. 2003 Aug;13 Suppl A:S4-9. Review.

PMID:
12914718
11.

Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.

Miyamoto L, Ebihara K, Kusakabe T, Aotani D, Yamamoto-Kataoka S, Sakai T, Aizawa-Abe M, Yamamoto Y, Fujikura J, Hayashi T, Hosoda K, Nakao K.

J Biol Chem. 2012 Nov 23;287(48):40441-7. doi: 10.1074/jbc.M112.384545. Epub 2012 Sep 28.

12.
13.

Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency.

McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA.

J Clin Endocrinol Metab. 2004 Sep;89(9):4258-63.

14.

Rationale for leptin-replacement therapy for severe lipodystrophy.

Oral EA, Chan JL.

Endocr Pract. 2010 Mar-Apr;16(2):324-33. doi: 10.4158/EP09155.RA. Review.

PMID:
20061299
15.

Leptin: from animals to humans.

Veniant MM, LeBel CP.

Curr Pharm Des. 2003;9(10):811-8. Review.

PMID:
12678880
16.

20 years of leptin: leptin in common obesity and associated disorders of metabolism.

DePaoli AM.

J Endocrinol. 2014 Oct;223(1):T71-81. doi: 10.1530/JOE-14-0258. Epub 2014 Jun 27. Review.

17.

The therapeutic potential of leptin.

Proietto J, Thorburn AW.

Expert Opin Investig Drugs. 2003 Mar;12(3):373-8. Review.

PMID:
12605561
18.

Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin.

Gómez R, Lago F, Gómez-Reino JJ, Gualillo O.

Expert Opin Ther Targets. 2009 May;13(5):583-91. doi: 10.1517/14728220902914834 . Review.

PMID:
19397477
19.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
20.

Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.

Rodríguez AJ, Neeman T, Giles AG, Mastronardi CA, Paz Filho G.

Arq Bras Endocrinol Metabol. 2014 Nov;58(8):783-97. Epub 2014 Nov 1. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk